Search Results - anti-cancer

4 Results

Sort By:

Translation Regulated (TR)-Mediated Gene Expression: Novel Expression and Reporter Vectors

This is a cell based vector system that is able to monitor the transition, in cell lines, from Cap dependent to Cap independent translation. This shift is critical in determining if a cell, that is placed under significant stress (such as treatment with a chemotherapeutic agent), recovers or undergoes programmed cell death (apoptosis). This information...

Published: 2/6/2014 | Inventor(s): Leon Carlock, Maria Cypher

Keywords(s): Animal Model, Anti-cancer, Cancer, Cancer risk, Cancer Therapies, Diagnostics, Imaging, Therapeutics

Category(s): Life Science, Diagnostics, Research tools, Assays, Cell lines

Repurposing AKT Inhibitors for the Treatment of Protein Misfolding and Protein Trafficking Diseases

Wayne State University researchers have demonstrated that inhibition of pro-survival kinase, AKT, using the transgene, Trb3, expressed in oligodendrocytes, leads to less brain white matter than controls. Moreover, Trb3 introduction into an animal model of the human disease, Pelizaeus Merzbacher disease (PMD) leads to less myelin thickness and fewer...

Published: 3/31/2014 | Inventor(s): Alexander Gow, Cherie Southwood

Keywords(s): Alzheimer's Disease, Anti-cancer, Neuro-disorders, Parkinson's

Category(s): Biotechnology, Life Science, Neurological disorders, Oncology, Therapeutics

Method For Treating and/or Imaging Breast Cancer Using Radioactive Iodine

This invention involves treating a breast cancer patient by the administration of a radioisotope of iodine in a dosage of between 5 and 50 milliCuries over the course of a day. The therapeutic composition is designed for mammary tissue uptake and includes an inorganic radioactive iodide salt (e.g., alkali metal, alkali earth or transition metal...

Published: 3/31/2014 | Inventor(s): James Rillema

Keywords(s): Anti-cancer, Breast Cancer, Cancer Therapies, Imaging, Therapeutics

Category(s): Therapeutics, Life Science, Oncology, Receptors/targets, Diagnostic, Imaging

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 2/6/2014 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other